Merck’s sales rise more than expected, lifts full-year outlook
🤖 D.R.A.F.T. Summary
Sales of top-selling cancer treatment Keytruda rose to $8.37-billion in the quarter, beating estimates
Outlets covering this story
The Globe and Mail
LEFT
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →